Omvoh (mirikizumab-mrkz) subcutaneous injection — Medica

Initial criteria

• Patient is age ≥ 18 years
• According to the prescriber, the patient will receive three induction doses with Omvoh intravenous within 3 months of initiating therapy with Omvoh subcutaneous
• Medication is prescribed by or in consultation with a gastroenterologist

Reauthorization criteria

• Patient has been established on Omvoh subcutaneous therapy for at least 6 months
• Patient meets at least ONE of the following: (a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (examples: fecal or serum markers, endoscopic assessment, or reduced corticosteroid dose); OR (b) Compared with baseline, patient experienced an improvement in at least one symptom (such as decreased pain, fatigue, stool frequency, and/or decreased rectal bleeding)

Approval duration

Initial: 6 months; Reauthorization: 1 year